Senomyx (NASDAQ: SNMX) and PAREXEL International (NASDAQ:PRXL) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Earnings & Valuation
This table compares Senomyx and PAREXEL International’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Senomyx||$23.04 million||2.70||-$10.68 million||($0.26)||-5.00|
This is a summary of current ratings for Senomyx and PAREXEL International, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Senomyx presently has a consensus price target of $2.00, indicating a potential upside of 53.85%. PAREXEL International has a consensus price target of $78.30, indicating a potential upside of Infinity. Given PAREXEL International’s stronger consensus rating and higher possible upside, analysts clearly believe PAREXEL International is more favorable than Senomyx.
Institutional and Insider Ownership
28.5% of Senomyx shares are owned by institutional investors. Comparatively, 87.5% of PAREXEL International shares are owned by institutional investors. 12.4% of Senomyx shares are owned by company insiders. Comparatively, 2.9% of PAREXEL International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Senomyx and PAREXEL International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
PAREXEL International beats Senomyx on 8 of the 10 factors compared between the two stocks.
Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.
Receive News & Ratings for Senomyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.